ADA2-Functionalized OMVs Remodel the Tumor Microenvironment in Pancreatic Cancer
Pharmaceutics · 27.07.2026 · 18 (8) · 920
DOI: 10.3390/pharmaceutics18080920 ↗Kurz gefasst
Fachartikel in der Zeitschrift Pharmaceutics, online erschienen am 27.07.2026. Verfasst von Vahid Khalaj und 9 weiteren Autor:innen. Beteiligte Einrichtung: Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA. Die Arbeit nennt 65 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NCI NIH HHS, NIH HHS, NIH Shared Instrumentation.
Abstract (Originalsprache)
Background/Objectives: Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with a desmoplastic, immunosuppressive tumor microenvironment enriched in extracellular adenosine. High adenosine levels disrupt anti-tumor immunity by engaging adenosine receptors on T cells, macrophages, and dendritic cells. In this context, strategies to reduce extracellular adenosine signaling within the TME are in focus. Among them, enzymatic degradation of extracellular adenosine levels has emerged as a promising approach to overcome immune suppression and restore anti-tumor immune responses.
Methods
Here, we engineered an E. coli strain to express a surface-bound form of a bacterial ADA2 enzyme and used the outer membrane vesicles produced by this strain as nanoparticles carrying the functional enzyme. Our data indicate robust surface expression and enzymatic activity of ADA2 on OMV particles.
Results
In a PDAC subcutaneous flank tumor model, intratumoral administration of OMV-ADA2 particles was associated with significantly increased infiltration of CD8+ T cells and Granzyme B expression and concomitant decreases in collagen deposition and α-smooth muscle actin (α-SMA) positive stromal cells, suggesting modulation of the desmoplastic stroma.
Conclusions
These findings support further investigation of OMV–bADA2 as a potential platform to modulate tumor metabolism and stroma, activate anti-tumor immunity, and serve as a carrier for co-delivery of additional anticancer modalities in PDAC.
Schlagwörter
Stichwörter der Autor:innen
Autor:innen und Institutionen
- Institute of Molecular Medicine, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
- Department of Pathology, Microbiology and Immunology, The University of Nebraska Medical Center, Omaha, NE 68198, USA.
- Fred & Pamela Buffett Cancer Center, The University of Nebraska Medical Center, Omaha, NE 68198, USA.
- Department of Pediatric Surgery, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
- Department of Internal Medicine, McGovern Medical School, The University of Texas Health Science Center at Houston, Houston, TX 77030, USA.
ORCID-Profile: Vahid Khalaj, Alyssa M Waller, MacKenzie V Demmel, Aidan Collier, Ana Maria Zaske, Jennifer M Bailey-Lundberg, Ali Azhdarinia
Förderung
- NCI NIH HHS
- NIH HHS
- NIH Shared Instrumentation
- United States Department of Defense
- John S. Dunn Foundation
- National Cancer Institute of the National Institutes of Health
- Department of Defense
Zitieren
APA
Khalaj, V., Waller, A. M., Demmel, M. V., Sardarni, U. K., Adams, J. T., Collier, A., Zaske, A. M., Momeny, M., Bailey-Lundberg, J. M., & Azhdarinia, A. (2026). ADA2-Functionalized OMVs Remodel the Tumor Microenvironment in Pancreatic Cancer. Pharmaceutics, 18(8), 920. https://doi.org/10.3390/pharmaceutics18080920
Vancouver
Khalaj V, Waller AM, Demmel MV, Sardarni UK, Adams JT, Collier A, et al. ADA2-Functionalized OMVs Remodel the Tumor Microenvironment in Pancreatic Cancer. Pharmaceutics. 2026;18(8):920. doi:10.3390/pharmaceutics18080920
BibTeX
@article{Khalaj2026,
author = {Khalaj, Vahid and Waller, Alyssa M and Demmel, MacKenzie V and Sardarni, Urvinder Kaur and Adams, Jack T and Collier, Aidan and Zaske, Ana Maria and Momeny, Majid and Bailey-Lundberg, Jennifer M and Azhdarinia, Ali},
title = {ADA2-Functionalized OMVs Remodel the Tumor Microenvironment in Pancreatic Cancer},
journal = {Pharmaceutics},
year = {2026},
volume = {18},
number = {8},
pages = {920},
doi = {10.3390/pharmaceutics18080920}
}
EUVIMED